Contract win could prove to be a turnaround for still-controversial CVS-Caremark merger; will medication adherence programs make a difference?
This round of PBM competition goes to CVS Caremark, which announced in late May that it had won the mail-order (and ancillary) business for the Blue Cross and Blue Shield Government-Wide Service Benefit Plan, also known as the Federal Employee Program (FEP), representing some five million covered lives. CVS Caremark already has had the retail pharmacy business from FEP. On the news, CVS Caremark’s stock rose 3.5% in mid-day trading, representing its highest price since July 2008, and Medco’s stock dropped 9%, according to the Wall Street Journal. The CVS Caremark announcement stated that the contract win was “based on the best overall value,” which implies some significant discounting of service fees.
There have been a number of disputes and disappointments involving CVS Caremark since its 2007 merger, creating a $99-billion/yr retailing behemoth, mostly involving Caremark trying to steer PBM clients toward its retail pharmacies. Less-than-stellar financial results have made analysts call for the merger to be unwound. Now, some financial analysts are saying that the model might prove itself for the longer term.
Branded pharmaceuticals, with some notable exceptions (specialty drugs with exclusive distribution agreements) are mostly indifferent to which PBMs handle them, although all PBMs compete to get the best price from manufacturers. But PBMs and retail pharmacy are competing intensely to manage adherence programs, which could prove to be a differentiator over time.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.